KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $209.0 million.

  • AbbVie's Share-based Compensation rose 1546.96% to $209.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $962.0 million, marking a year-over-year increase of 1032.11%. This contributed to the annual value of $911.0 million for FY2024, which is 2195.45% up from last year.
  • AbbVie's Share-based Compensation amounted to $209.0 million in Q3 2025, which was up 1546.96% from $179.0 million recorded in Q2 2025.
  • AbbVie's Share-based Compensation's 5-year high stood at $410.0 million during Q1 2025, with a 5-year trough of $107.0 million in Q2 2022.
  • In the last 5 years, AbbVie's Share-based Compensation had a median value of $179.0 million in 2023 and averaged $201.0 million.
  • Per our database at Business Quant, AbbVie's Share-based Compensation tumbled by 3270.44% in 2022 and then soared by 6728.97% in 2023.
  • AbbVie's Share-based Compensation (Quarter) stood at $129.0 million in 2021, then increased by 2.33% to $132.0 million in 2022, then decreased by 5.3% to $125.0 million in 2023, then soared by 31.2% to $164.0 million in 2024, then increased by 27.44% to $209.0 million in 2025.
  • Its Share-based Compensation was $209.0 million in Q3 2025, compared to $179.0 million in Q2 2025 and $410.0 million in Q1 2025.